Managing Painful Diabetic Neuropathy

Diabetic peripheral neuropathy (DPN) is one of the most common complications associated with diabetes. Recent esti­mates show that DPN affects approximately 50% of people with diabetes in the United States. Painful diabetic neuropathy (PDN) has been defined as the clinical scenario in which neuropathic pain arises as a direct consequence of DPN. About 25% of people with diabetes will get PDN.

Current Options

Several prescription medications are available for DPN and may provide a degree of pain relief, but these agents can potentially cause side effects. Another option for PDN is transcutaneous electrical nerve stimulation (TENS). With TENS, low-voltage electrical currents are delivered directly to the area of pain or at pressure points. Clinical studies assessing the efficacy of TENS have shown encouraging results for pain relief. Unfortunately, traditional TENS systems consist of general purpose devices with cables and electrodes that are often not compatible with an active lifestyle.

A Simple, Convenient Therapy

The Sensus Pain Management System (developed by NeuroMetrix, Inc.) was cleared by the FDA for use by patients suffering from chronic pain, including PDN. The system is a lightweight, self-contained TENS device that is configured to patients’ unique physiology. In contrast to general purpose TENS, Sensus is simple and convenient. It’s worn discretely under clothing below the knee and without wires or complex controls. Patients initiate a 60-minute therapy session with the push of a button. Pain relief typically begins within 15 minutes and often lasts for 30 minutes following the session. In addition, Sensus is the only TENS device cleared by the FDA for use during sleep. The device provides a continuous mode delivering a therapy session every other hour for pain control during sleep.

Positive Patient Response

Sensus has provided encouraging results in various clinical settings. Patients using the device describe the stimulation as a buzzing or light pressure sensation that fades into the background of daily activities. They appreciate the control that the system provides and prefer the “on-demand” initiation of therapy the ease in which they can adjust stimulation intensity. Many patients have commented on the benefits of the device for nighttime chronic pain that interrupts sleep.

Another positive feature of Sensus is that it can either complement medications or be prescribed alone. The device can be effective as monotherapy when clinical assessments indicate that pain medications are not well tolerated or are ineffective. The system serves as another safe and effective treatment option to help patients suffering from PDN to get the pain relief they need and restore quality of life.


View Comments

  • I love what you said about therapy and how it is convenient. Visiting a podiatrist seems like the right thing to do if you have foot pain. My friend has diabetes, so I'll help him find the best foot doctor in town.

Recent Posts

India bans e-cigarettes in setback for Juul and Philip Morris

By Aditya Kalra and Aftab Ahmed NEW DELHI (Reuters) - India banned the production, import and sale of electronic cigarettes…

36 mins ago

Thailand culls 200 pigs amid heightened fears over African swine fever

By Panarat Thepgumpanat and Patpicha Tanakasempipat BANGKOK (Reuters) - Thailand has culled more than 200 pigs this week, authorities said…

51 mins ago

Roche bid to recycle Gazyva for lupus nephritis wins FDA breakthrough tag

By John Miller ZURICH (Reuters) - Roche has won the U.S. Food and Drug Administration's breakthrough therapy tag for its…

2 hours ago

Scientists release sterile mosquitoes in Burkina to fight malaria

By Thiam Ndiaga SOUROUKOUDINGA, Burkina Faso (Reuters) - Scientists in Burkina Faso have deployed a new weapon in the fight…

3 hours ago

South Korea confirms second case of deadly African swine fever, pledges vigilance

By Jane Chung SEOUL (Reuters) - South Korea has confirmed a second case of African swine fever at a pig…

7 hours ago

New York state ban on flavored e-cigarettes given final approval

By Alex Dobuzinskis (Reuters) - New York became the second state to ban flavored e-cigarettes on Tuesday after its Democratic…

10 hours ago